8-K: Hims & Hers Reports Strong 2025 Growth, Eyes Global Expansion

Hims & Hers Health, Inc. announced robust financial results for Q4 and full year 2025, with revenue up 59% year-over-year to $2.35 billion, driven by subscriber growth and strategic international expansion.

Summary

• Full year 2025 revenue reached $2.35 billion, marking a 59% increase year-over-year.
• Fourth quarter 2025 revenue grew 28% year-over-year to $618 million.
• Adjusted EBITDA for full year 2025 was $318 million, an 80% increase year-over-year, and $66 million for Q4 2025, up 23% year-over-year.
• The subscriber base expanded to over 2.5 million by the end of 2025, a 13% increase year-over-year and a 40,000 increase quarter-over-quarter.
• Monthly Revenue per Average Subscriber increased to $83, up 28% year-over-year for the full year and 11% year-over-year for the fourth quarter.
• Net income for full year 2025 was $128.4 million, compared to $126.0 million in 2024 (which included a $68.0 million valuation allowance release).
• Net income for Q4 2025 was $20.6 million, a decrease from $26.0 million in Q4 2024.
• Gross margin for full year 2025 was 74%, down from 79% in 2024, and 72% for Q4 2025, down from 77% in Q4 2024.
• Free Cash Flow for full year 2025 was $57.4 million, a significant decrease from $198.3 million in 2024, and was negative $(2.6) million for Q4 2025, down from $59.5 million in Q4 2024.
• The company expanded internationally through the acquisition of ZAVA, the launch of Hims and Hers Canada, and a definitive agreement to acquire Eucalyptus, which has an annual revenue run-rate (ARR) north of $450 million USD.
• New specialties launched in 2025 include hormone therapies (testosterone support, menopause, perimenopause) and lab testing.
• Over 1.6 million subscribers are utilizing personalized solutions, representing more than 30% year-over-year growth.
• Over the last three years, the company invested over $300 million in capital spending, expanding its facility footprint in the US to over 1 million square feet.
• A share repurchase authorization of up to $250 million was announced in November 2025, with approximately $80 million of Class A common stock repurchased in Q4 2025, leaving $225 million remaining.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report demonstrating robust top-line growth, strategic international expansion, and significant investment in future capabilities, despite some short-term margin and cash flow pressures related to these growth initiatives.

Positives

• Full year 2025 revenue grew 59% year-over-year to $2.35 billion, demonstrating robust top-line expansion.
• Adjusted EBITDA for full year 2025 increased 80% year-over-year to $318 million, indicating strong operational leverage.
• The subscriber base grew to over 2.5 million, a 13% year-over-year increase, reflecting continued customer acquisition and retention.
• Monthly Revenue per Average Subscriber increased 28% year-over-year for the full year to $83, showing enhanced customer value.
• Successful international expansion with the acquisition of ZAVA, launch in Canada, and the definitive agreement to acquire Eucalyptus, which has an ARR north of $450 million USD and triple-digit YoY ARR growth in 2025.
• Expansion into new specialties like hormone therapies and lab testing has shown strong customer resonance, with 95% of testosterone support users experiencing an average increase of over 80% in testosterone levels after 2 months.
• Efficient customer acquisition with marketing payback periods trending closer to 6-7 months, indicating effective marketing spend.
• Over 1.6 million subscribers are utilizing personalized solutions, growing over 30% year-over-year, highlighting the success of tailored care models.
• Significant investment of over $300 million in physical infrastructure over three years, expanding facility footprint to over 1 million square feet, supports future growth and personalized care capabilities.
• Maintained a leadership position in the U.S. telehealth market, being roughly twice the size of the next largest provider in 2025.
• A share repurchase authorization of up to $250 million is in place, with $80 million already repurchased in Q4 2025, signaling confidence in intrinsic value and a strategy to offset dilution.

Negatives

• Gross margin decreased approximately 500 basis points year-over-year to 72% in Q4 2025 and 74% for FY 2025, primarily due to international market contributions, new offerings, and shorter shipping cadences in weight loss.
• Net income for Q4 2025 decreased to $20.6 million from $26.0 million in Q4 2024.
• Free Cash Flow turned negative in Q4 2025 at $(2.6) million, compared to positive $59.5 million in Q4 2024, primarily driven by increased capital expenditures.
• Full year 2025 Free Cash Flow significantly decreased to $57.4 million from $198.3 million in 2024, reflecting substantial investments.
• Technology and development expenses increased as a percentage of revenue from 5% to 7% (GAAP) and 4% to 6% (non-GAAP) in Q4 and FY 2025, reflecting ongoing investment.
• General and administrative expenses increased as a percentage of revenue from 10% to 12% (GAAP) and 7% to 9% (non-GAAP) in Q4 and FY 2025, due to Zava integration and new leadership hiring.
• The company incurred approximately $1 billion of debt on its balance sheet, primarily from a May 2025 convertible note offering.

Risks

• Inability to predict with reasonable certainty the ultimate outcome of certain components of forward-looking Adjusted EBITDA reconciliations, including market-related assumptions not within the company's control.
• The ongoing ability to provide access to compounded semaglutide through the platform is a key assumption for future outlook.
• Potential changes to current business relationships could impact financial performance.
• The company is subject to risks and uncertainties described in the Risk Factors and other sections of its most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K.
• Regulatory environment, financial condition, results of operations, shortand long-term business operations, objectives, strategy, and financial needs are subject to various factors.
• Market acceptance, user experience, customer retention, brand development, customer acquisition costs, operating efficiencies and leverage, pricing decisions, changes in product or offering mix, and the timing and market acceptance of new products or offerings could differ from expectations.
• The timing and anticipated effect of pending or recently completed acquisitions, such as Eucalyptus, are subject to customary closing conditions, including regulatory approvals.
• The company's ability to comply with extensive, complex, and evolving legal and regulatory requirements, including state and federal healthcare, privacy, and consumer protection laws, poses a risk.
• The effect or outcome of litigation or governmental actions or statements in relation to legal and regulatory requirements could materially impact results.
• Forward-looking statements are not guarantees of future performance, and actual results may differ materially due to various factors.
• Information from independent industry organizations and other third-party sources regarding the industry and markets is inherently imprecise and has not been independently verified.

Future Outlook

Hims & Hers projects Q1 2026 revenue between $600 million and $625 million, with Adjusted EBITDA ranging from $35 million to $55 million (6% to 9% margin). For the full year 2026, the company expects revenue of $2.7 billion to $2.9 billion and Adjusted EBITDA of $300 million to $375 million (11% to 13% margin). These forecasts exclude potential contributions from the Eucalyptus acquisition, expected to close mid-2026, and assume continued access to compounded semaglutide. The company reiterates its 2030 financial ambitions of achieving at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.

Management Comments

• Andrew Dudum, CEO and Co-Founder: "More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we're well on our way to becoming the global leader in consumer health."
• Andrew Dudum, CEO and Co-Founder: "In 2025, we made it possible for more customers across the world to depend on us for access to care across an expanding range of conditions. From launching hormone therapies and diagnostics, introducing Labs to unlock deeper health insights, and taking meaningful steps to grow internationally, the investments we're making today position us to set a new standard in healthcare for people everywhere."
• Andrew Dudum, CEO and Co-Founder: "The continued growth and diversification of our platform is helping to create a world where proactive, preventative, and personalized care can feel like a luxury without actually costing like one."
• Yemi Okupe, Chief Financial Officer: "Our financial results in 2025 demonstrate the power of scaling a deeply personalized consumer health platform."
• Yemi Okupe, Chief Financial Officer: "Revenue grew 59% year-over-year to $2.35 billion as we expanded our subscriber base and increased engagement across specialties by bringing new sources of value to millions of customers."
• Yemi Okupe, Chief Financial Officer: "With a strong balance sheet and robust operating cash flow from tenured specialties in our domestic operations, we have the flexibility to invest in scaling new specialties, advancing our technology and infrastructure, and expanding internationally, all supporting our path toward our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA."

Industry Context

StockSavvy.ai notes that Hims & Hers' strong growth in telehealth, particularly in specialized areas like weight loss (GLP-1s), dermatology, and sexual health, aligns with broader industry trends towards personalized, accessible, and preventative care. The company's aggressive international expansion and investment in AI and physical infrastructure position it to capitalize on the global demand for digital health solutions, potentially disrupting traditional healthcare models. The focus on compounded GLP-1s and new specialties like hormone therapy and lab testing reflects a strategic move to capture larger, underserved markets within the evolving healthcare landscape.

Comparison to Industry Standards

• Hims & Hers was approximately twice the size of the next largest U.S. telehealth provider in 2025, indicating a strong market leadership position in the U.S. across key specialties like Sexual Health, Dermatology, Mental Health, and Weight Loss.
• The rapid scaling of the Weight Loss offering, reaching over $100 million in annual revenue in roughly nine months, significantly outperforms the time taken for older specialties like Sexual Health (three years) and Hair Loss (four years) to reach the same milestone, demonstrating improved efficiency in new market penetration.
• The acquisition target, Eucalyptus, reported triple-digit year-over-year Annual Revenue Run-rate (ARR) growth in each quarter of calendar year 2025 while operating within line of sight of profitability, suggesting it is a high-growth, efficient digital health platform comparable to other successful industry innovators.

Legal Proceedings

• The company faces risks related to the effect or outcome of litigation or governmental actions or statements in relation to extensive, complex, and evolving legal and regulatory requirements applicable to its business.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through aggressive growth and strategic investments, balanced by short-term pressures on profitability and cash flow due to these investments. The share repurchase program aims to offset dilution and capitalize on market value disconnects.
• Customers: Expanded access to personalized care across new specialties (e.g., weight loss, hormone therapy, labs) and an improved user experience driven by technology and AI.
• Employees: Continued hiring of world-class executive leadership and supporting talent in key areas such as engineering, product development, and AI to support growth initiatives.
• Partners: The platform aims to become a 'curator of best-in-class health services,' offering partners access to millions of potential new customers and data-driven insights.
• Creditors: Increased debt on the balance sheet due to the May 2025 convertible note offering.

Next Steps

• Continue efforts across five key growth levers in 2026: entering new specialties, utilizing technology/AI, broadening access to personalized care, establishing partnerships, and expanding global reach.
• Build out additional sterile injectable capacity to support Weight Loss and Hormonal Support treatments.
• Bring on additional capacity for unique form factors and multi-condition solutions.
• Verticalize at-home blood draw and lab testing capabilities following the acquisition and integration of YourBio.
• Become a leading provider of branded GLP-1 medications in international markets in 2026.
• Close the acquisition of Eucalyptus in mid-2026, subject to customary closing conditions and regulatory approvals.
• Host a conference call on February 23, 2026, at 5:00 p.m. ET to review the fourth quarter and full year 2025 results.

Key Dates

Recommendation

The company demonstrates strong revenue and Adjusted EBITDA growth, driven by successful expansion into new specialties and international markets. However, the decline in gross margin, Q4 net income, and negative Q4 free cash flow due to significant capital expenditures and integration costs warrant a cautious approach. While the long-term vision and 2030 targets are ambitious, the immediate financial impact of these investments suggests a 'Hold' as the market assesses the execution and return on these substantial outlays.

Keywords

Telehealth, Personalized Healthcare, Digital Health, Hims & Hers, Q4 2025 Earnings, Financial Results, Subscriber Growth, GLP-1, Weight Loss, Dermatology, Sexual Health, Hormone Therapy, Lab Testing, International Expansion, Eucalyptus Acquisition, Adjusted EBITDA, Revenue